Form 4: United Therapeutics Director Rothblatt Exercises and Sells Stock Options Under 10b5-1 Plan

Martine Rothblatt, a director at United Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, a director at United Therapeutics Corp, filed a Form 4 detailing changes in beneficial ownership.
• The transactions involved the exercise of stock options at a price of $129.49 and subsequent sale of common stock on May 16 and May 17, 2024.
• These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
• The plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
• The sales occurred at varying prices, with weighted average prices reported for each transaction date.
• Rothblatt also holds shares indirectly through various family trusts.
• Following the reported transactions, Rothblatt directly owns 130 shares and indirectly owns a significant number of shares through various trusts.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of stock transactions by a company insider, executed under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment.

Future Outlook

The 10b5-1 trading plan will continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.

Industry Context

Form 4 filings are standard practice for corporate insiders to report transactions in their company's stock, providing transparency to the market.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among corporate executives to avoid accusations of insider trading.
• These plans allow insiders to sell shares at predetermined times and prices, regardless of any material non-public information they may possess.
• Comparable companies such as Gilead Sciences, Amgen, and Biogen also see frequent Form 4 filings related to stock option exercises and sales by their executives.

Key Dates